PerkinElmer said today it agreed to acquire BioLegend, a provider of life science antibodies and reagents, for approximately $5.25 billion in cash and stock—the largest acquisition in the buyer’s ...
PerkinElmer has entered into an agreement to acquire BioLegend, a global developer and manufacturer, in a deal valued at $5.25 billion. PerkinElmer has entered into an agreement on July 26, 2021 to ...
PerkinElmer, Inc. (NYSE: PKI) has announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback